diabetestalk.net

Dapagliflozin/metformin 5/1000

Xigduo Xr (dapagliflozin/metformin) Dosing, Indications, Interactions, Adverse Effects, And More

Xigduo Xr (dapagliflozin/metformin) Dosing, Indications, Interactions, Adverse Effects, And More

Individualize starting dose based on patients current therapy Take once daily in morning with food, with gradual dose escalation to reduce the adverse GI effects due to metformin Adjust dose based on effectiveness and tolerability; not to exceed daily dose of dapagliflozin 10 mg and metformin 2000 mg (ie, 2 tablets of 5mg/1000mg) Patients taking an evening dose of metformin XR should skip their last dose before starting dapagliflozin/metformin the following morning eGFR 30-45 mL/min/1.73 m: Not recommended to initiate treatment Monitor eGFR at least annually or more often for those at risk for renal impairment (eg, elderly) If eGFR falls below 45mL/min/1.73 m while taking metformin, risks and benefits of continuing therapy should be evaluated If eGFR falls below 30 mL/min/1.73 m: while taking metformin, discontinue the drug Correct volume depletion before initiating in patients not previously treated with dapagliflozin Not for type 1 diabetes mellitus or diabetic ketoacidosis eGFR 30-60 mL/min (8-28.3%; placebo 6.5-16.1%) Age 65 yr and eGFR 30-60 mL/min (7-35.1%; placebo 4.9-19.1%) Female genital mycotic infections (6.9-8.4%) Male genital mycotic infections (2.7-2.8%) Patients on loop diuretics (0-9.7%; 1.8-2.5%) Patients with moderate renal impairment, GFR 30-60 mL/min (0.9-1.9%; placebo 1.5-1.9%) Acute kidney injury and impairment in renal function Cholestatic, hepatocellular, and mixed hepatocellular liver injury Lactic acidosis caused by metformin accumulation (plasma concentration >5 mcg/mL) is a rare but potentially severe consequence; if it occurs, mortality is ~50% Risk increases with certain conditions (eg, renal impairment, sepsis, dehydration, excess alcohol intake, hepatic impairment, and acute CHF) Onset is subtle, accompanied only by nonspecific symptoms Continue reading >>

New Metformin Combination Medicine Approved For Type 2 Diabetes

New Metformin Combination Medicine Approved For Type 2 Diabetes

On October 30, the US Food and Drug Administration (FDA) approved the combination oral diabetes drug Xigduo XR for use, along with a healthful diet and exercise, in adults with Type 2 diabetes. The medicine, a development of AstraZeneca, combines dapagliflozin (brand name Farxiga), an SGLT2 inhibitor, and extended-release metformin (Glucophage XR and others). In the process of filtering the blood, the kidneys typically reabsorb all the filtered glucose and return it to the bloodstream. One of the main proteins responsible for this reabsorption is SGLT2. By inhibiting the action of SGLT2, Farxiga blocks the reabsorption of glucose by the kidneys, promoting a loss of glucose in the urine and lowering blood glucose levels. Metformin works by decreasing the amount of glucose made by the liver and by improving insulin sensitivity in the liver, muscle, and fat cells. Xigduo XR, the first once-daily combination tablet of an SGLT2 inhibitor and extended-release metformin approved in the United States, will be offered in doses of 5 milligrams of dapagliflozin/500 milligrams of metformin, 5 milligrams of dapagliflozin/1,000 milligrams of metformin, 10 milligrams of dapagliflozin/500 milligrams of metformin, and 10 milligrams of dapagliflozin/1,000 milligrams of metformin to be taken once a day in the morning with food. This medicine should not be used in people with Type 1 diabetes, diabetic ketoacidosis (a potentially life-threatening condition marked by a chemical imbalance in the body), or moderate to severe kidney impairment. Because of the inclusion of metformin, Xigduo XR carries the risk of a rare but serious metabolic complication known as lactic acidosis. The most commonly reported side effects of Farxiga plus metformin compared to placebo (inactive treatment) plus metfo Continue reading >>

Xigduo Xr 5/1000 56 Tablets (dapagliflozin 5 Mg + Metformin 1g Xr)

Xigduo Xr 5/1000 56 Tablets (dapagliflozin 5 Mg + Metformin 1g Xr)

Xigduo XR 5/1000 56 Tablets (Dapagliflozin 5 mg + Metformin 1g XR) Australian Government regulations specify that you need to send us the original prescription by mail before we can dispense your prescription. You can do this for free using our Reply Paid address: Note: Choosing to keep your repeat scripts with us means you wont have to send your scripts to us in the future. Ask our pharmacists or call us directly on 1300 280 278 How to order your prescription medication online 1. Using our smart search box at the top of our website is the easiest way to find your desired medication. Alternatvely you can click on the green "Prescription" button in the top horizontal menu of our website. From there use our search box to type the name of the medication or use the left side navigation to browse via the letter your script name starts with. 2. Choose the type of script price you're eligible for ( learn more ) and add the desired quantity to your cart, by pressing the pink "Add to Cart" button. You have the option of adding any other items from our website. Once you have finished shopping, proceed to checkout to complete your purchase. Note: PayPal cannot be used as your payment method when purchasing prescriptions. 3. Australian Government regulations specify that you need to send us the original prescription by mail before we can dispense your prescription. You can do this for free using our Reply Paid address: Note: Choosing to keep your repeat scripts with us means you wont have to send your scripts to us in the future. 4. Your parcel will be dispatched and should arrive within 3-7 business days from the time we receive your script. Depending on your eligibility for entitlement, you may receive different subsidy levels from the Australian Government for your prescription Continue reading >>

Bioequivalence Study Of Combination Tablets Of Saxagliptin / Dapagliflozin / Metformin Xr (extended-release) And Dapagliflozin / Metformin Xr Relative To Individual Components In Healthy Subjects

Bioequivalence Study Of Combination Tablets Of Saxagliptin / Dapagliflozin / Metformin Xr (extended-release) And Dapagliflozin / Metformin Xr Relative To Individual Components In Healthy Subjects

You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov Identifier: NCT03138356 Information provided by (Responsible Party): Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information In this integrated, Phase I study, the safety, tolerability, food effect, and pharmacokinetic (PK) properties of Fixed-Dose Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects will be investigated. Drug: 2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet Drug: 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet Drug: 5 mg dapagliflozin / 850 mg metformin XR FDC Drug: 5 mg dapagliflozin / 1000 mg metformin XR FDC Drug: 2.5 mg ONGLYZA (saxagliptin) tablet Drug: 5 mg Forxiga (dapagliflozin) tablet Drug: 500 mg Glucophage XR This study will be an open-label, randomized, 3-period, 3-treatment, single-dose crossover study in healthy subjects (males and females), performed at a single study center, conducted in 3 cohorts. A total of 126 healthy male or female subjects (3 cohorts of 42 subjects each [each cohort consisting of 3 treatments]) will be randomized in this study to ensure that at Continue reading >>

Xigduo Xr (dapagliflozin,metformin) Dosage, Indication, Interactions, Side Effects | Empr

Xigduo Xr (dapagliflozin,metformin) Dosage, Indication, Interactions, Side Effects | Empr

Moderate-to-severe renal impairment (eGFR <60mL/min/1.73m2), ESRD, or on dialysis. Metabolic acidosis, diabetic ketoacidosis. Increased risk of metformin-associated lactic acidosis in renal or hepatic impairment, concomitant use of certain drugs (eg, cationic drugs), 65yrs of age, undergoing radiological contrast study, surgery and other procedures, hypoxic states, and excessive alcohol intake; discontinue if lactic acidosis occurs. Discontinue at time of, or prior to intravascular iodinated contrast imaging in patients with a history of hepatic impairment, alcoholism, heart failure, or will be given intra-arterial contrast; reevaluate eGFR 48hrs after procedure and restart therapy if renally stable. Correct volume depletion before initiating. Monitor for symptomatic hypotension in renal impairment (eGFR <60mL/min/1.73m2), elderly, low systolic BP, or on loop diuretics. Assess for ketoacidosis in presence of signs/symptoms of metabolic acidosis, regardless of blood glucose levels; discontinue if suspected, evaluate and treat; consider risk factors before initiation (eg, pancreatic insulin deficiency, caloric restriction, alcohol abuse). Assess renal function prior to starting and periodically thereafter; more frequently in elderly. Risk of acute kidney injury in hypovolemia, chronic renal insufficiency, CHF, and concomitant drugs (eg, diuretics, ACEIs, ARBs, NSAIDs). Consider temporarily discontinuing in reduced oral intake or fluid losses; monitor for acute kidney injury; discontinue and treat if occurs. Elderly, debilitated, uncompensated strenuous exercise, malnourished or deficient caloric intake, adrenal or pituitary insufficiency, or alcohol intoxication: increased risk of hypoglycemia. Monitor for genital mycotic infections, UTIs, hematology (esp. serum Vit. B12 Continue reading >>

Xigduo Xr Oral : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - Webmd

Xigduo Xr Oral : Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - Webmd

Headache , diarrhea , nausea , vomiting , runny nose , or sore throat may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly. If stomach symptoms return later (after taking the same dose for several days or weeks), tell your doctor right away. Stomach symptoms that occur after the first days of your treatment may be signs of lactic acidosis . An empty tablet shell may appear in your stool. This effect is harmless because your body has already absorbed the medication . Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. Tell your doctor right away if you have any serious side effects, including: signs of a urinary tract infection (such as burning/painful/frequent/urgent urination, pink/bloody urine), signs of kidney problems (such as change in the amount of urine, swelling legs/feet). Use of this medication may result in a new yeast infection in the vagina or penis . You are more likely to get a yeast infection if you have had yeast infections in the genital area before. Uncircumcised men are also at an increased risk for infections. Tell your doctor right away if you have signs of yeast infection in the vagina (such as unusual vaginal discharge /burning/ itching /odor) or in the penis (such as redness/ itching /swelling of the penis, unusual discharge from the penis). Your doctor may direct you to use nonprescription antifungal products to treat these infections. Tell your doctor if your condition persists or worsens after treatment. This medication does not usually cause low blood sugar ( hypoglycemia ). Low blood sugar may occur if this drug is prescribed with oth Continue reading >>

Xigduo Xr Dosage & Drug Information | Mims.com Malaysia

Xigduo Xr Dosage & Drug Information | Mims.com Malaysia

Hypersensitivity. Diabetic ketoacidosis, diabetic pre-coma; acute conditions w/ the potential to alter renal function eg, dehydration, severe infection, shock or intravascular administration of iodinated contrast agents; acute or chronic disease which may cause tissue hypoxia eg, cardiac or resp failure, pulmonary embolism, recent MI, shock, acute significant blood loss, sepsis, gangrene, pancreatitis; during or immediately following surgery where insulin is essential, elective major surgery; hepatic impairment; acute alcohol intoxication, alcoholism. Moderate or severe renal impairment (CrCl <60 mL/min or eGFR <60 mL/min/ 1.73 m2). Hepatic impairment. Pregnancy & lactation. Not to be used in patients w/ type 1 DM; treatment of diabetic ketoacidosis. Lactic acidosis; ketoacidosis; pyelonephritis or urosepsis. Patients in antihypertensive or diuretic therapy, or when starting treatment w/ NSAID. Discontinue use prior to or at the time of iodinated contrast agent administration & not to be reinstituted until 48 hr afterwards. CV collapse (shock), acute CHF & MI. Loss of blood glucose control; risk of hypoglycaemia. Discontinue use 48 hr before elective surgery w/ general, spinal or epidural anaesth. Patients receiving loop diuretics or vol depleted. Routine serum vit B12 measurements at 2-3 yr intervals. Acute or chronic excessive alcohol intake. May affect ability to drive & use machines. Moderate renal impairment & severe hepatic impairment, clinical or laboratory evidence of hepatic disease. Not to be used in severe renal impairment. Elderly 80 yr. Continue reading >>

Dapagliflozin And Metformin

Dapagliflozin And Metformin

Prices and Coupons for 60 tablets of Xigduo XR 5mg/1000mg Xigduo XR 5mg-1000mg Extended-Release Tablet This medicine is a pink, oval tablet imprinted with "1071 5/1000". By providing your email address, you agree to receive emails containing coupons, refill reminders and promotional messages from GoodRx. You can unsubscribe anytime. Put GoodRx discounts on your home screen by downloading our top-rated mobile apps for iOS and Android for free GoodRx gathers prices and discounts from multiple sources, including published price lists, drug manufacturers, claims information and data provided to us by pharmacies. Our coupons are provided by Pharmacy Benefit Managers (PBMs), who maintain contracts with pharmacies to provide discounts. The prices we show are our best estimate; while we believe our data to be accurate, prices change frequently and we cant guarantee that the price we display will exactly match the price you receive at the pharmacy. To find your exact price, please contact the pharmacy (and note that the pharmacy will need to process the information shown on your coupon to confirm the price.)GoodRx provides no warranty for any pricing data or other information. We are not sponsored by or affiliated with any of the pharmacies identified in our price comparisons. All trademarks, brands, logos and copyright images are property of their respective owners and rights holders. All data provided is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. Please seek medical advice before starting, changing or terminating any medical treatment.In all states except Tennessee, GoodRx is considered a marketer of prescription discount cards. In Tennessee, GoodRx is registered as a Prescription Drug Discount Continue reading >>

Xigduo (dapagliflozin, Metformin)

Xigduo (dapagliflozin, Metformin)

What is Xigduo used for? Xigduo tablets are licensed for use in people with type 2 diabetes whose blood sugar is not controlled by the maximum tolerated dose of metformin alone or who are already taking metformin and dapagliflozin as separate tablets. Xigduo tablets can also be used for people with type 2 diabetes whose blood sugar is not sufficiently controlled by other antidiabetic medicines. It can be added to treatment with a sulphonylurea such as gliclazide or glibenclamide, or to treatment with insulin. How does Xigduo work? In type 2 diabetes the cells in the body become resistant to the action of insulin. Insulin is the main hormone responsible for controlling the level of sugar (glucose) in the blood. It makes cells in the body remove sugar from the blood. When the cells are resistant to insulin this makes blood sugar levels rise too high. Metformin is a type of antidiabetic medicine known as a biguanide. It works in a number of ways to decrease the amount of sugar in the blood. Firstly, it reduces the amount of sugar produced by cells in the liver. Secondly, it increases the sensitivity of muscle cells to insulin. This enables these cells to remove sugar from the blood more effectively. Finally, it delays absorption of sugar from the intestines into the bloodstream after eatingso that there is less of a spike in blood sugar levels after meals. Dapagliflozin works in the kidneys, where it allows the body to excrete excess glucose from the blood into the urine. Normally, when the kidneys filter and clean the blood, glucose is filtered out of the blood at the same time. The glucose is then reabsorbed back into the blood by a mechanism called the sodium-glucose co-transporter 2 (SGLT2). The kidneys normally reabsorb glucose back into the blood even when the levels Continue reading >>

Xigduo Xr (dapagliflozin And Metformin Hcl Extended-release Tablets): Side Effects, Interactions, Warning, Dosage & Uses

Xigduo Xr (dapagliflozin And Metformin Hcl Extended-release Tablets): Side Effects, Interactions, Warning, Dosage & Uses

(dapagliflozin and metformin HCl) Extended-Release Tablets Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels ( > 5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally > 5 mcg/mL [see WARNINGS AND PRECAUTIONS ]. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information [see DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , WARNINGS AND PRECAUTIONS , DRUG INTERACTIONS , and Use in Specific Populations ]. If metformin-associated lactic acidosis is suspected, immediately discontinue XIGDUO XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see WARNINGS AND PRECAUTIONS ]. XIGDUO XR (dapagliflozin and metformin HCl)extended-release tablets contain two oral antihyperglycemic medications usedin the management of type 2 diabetes : dapagliflozin and metforminhydrochloride. Dapagliflozin is described chemic Continue reading >>

Xigduo Xr 5/1000 (extended Release Tablets)

Xigduo Xr 5/1000 (extended Release Tablets)

Xigduo XR 5/1000 (Extended release tablets) Xigduo XR 5/1000 (Extended release tablets) Xigduo XR 5/1000 (Extended release tablets) Consumer medicine information (CMI) leaflet Please read this leaflet carefully before you start using Xigduo XR 5/1000 (Extended release tablets). Download CMI (PDF) Download large text CMI (PDF) This leaflet answers some common questions about XIGDUO XR. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking XIGDUO XR against the benefits they expect it will have for you. If you have any concerns about taking this medicine, ask your doctor or pharmacist. XIGDUO XR is a prescription medicine used with diet, exercise and sometimes other medicines such as insulin, a sulfonylurea, or a dipeptidyl peptidase (DPP-4) inhibitor to control the levels of blood sugar (glucose) in patients with type 2 diabetes mellitus. Type 2 diabetes mellitus (also called non-insulin-dependent diabetes mellitus, or NIDDM) is the condition of having high levels of blood sugar (hyperglycaemia). This is usually because your body does not make enough insulin and /or the insulin that your body produces does not work as well as it should. Left uncontrolled, the build-up of high levels of sugar in your blood can lead to serious medical problems. The main goal of treating type 2 diabetes is to control your blood sugar to a normal level. Lowering and controlling blood sugar may help prevent or delay complications of diabetes, which include kidney disease, blindness and amputation. XIGDUO XR contains two active ingredients, dapagliflozin and metformin hydrochloride. Dapagliflozin is a member of a class of medicines you take by Continue reading >>

Dapagliflozin 5 Mg / Metformin Hcl 1000 Mg 24hr Extended Release Oral Tablet

Dapagliflozin 5 Mg / Metformin Hcl 1000 Mg 24hr Extended Release Oral Tablet

It is very important to know about what medicine is given by the doctor, for what condition, and when it needs to be taken in what dose. This information given by the doctor is called Prescription. The patients should be familiar with the medicine prescription, and the details about the medicine before purchasing it and using it. Some medications need not be prescribed by healthcare practitioners and can be purchased and used without prescription by the patients; these are called over-the-counter medications. Read the drug prescription information of Dapagliflozin 5 MG / metFORMIN HCl 1000 MG 24HR Extended Release Oral Tablet before taking it. Dapagliflozin 5 MG / metFORMIN HCl 1000 MG 24HR Extended Release Oral Tablet uses Dapagliflozin 5 MG / metFORMIN HCl 1000 MG 24HR Extended Release Oral Tablet - Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1) ]. - Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and h Continue reading >>

Xigduo Xr: Uses, Dosage & Side Effects - Drugs.com

Xigduo Xr: Uses, Dosage & Side Effects - Drugs.com

Generic Name: dapagliflozin and metformin (DAP a gli FLOE zin and met FOR min) Xigduo XR extended release tablets contain a combination of dapagliflozin and metformin . Dapagliflozin and metformin are oral diabetes medicines that help control blood sugar levels. Dapagliflozin works by helping the kidneys get rid of glucose from your bloodstream. Metformin lowers glucose production in the liver and also causes your intestines to absorb less glucose. Xigduo XR is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus . Xigduo XR is not for treating type 1 diabetes. Men's Health Month And Movember: Raising The Profile Of Men's Health One Stache At A Time You should not use Xigduo XR if you have moderate to severe kidney disease, if you are on dialysis, or if you have metabolic acidosis. Xigduo XR is not for treating type 1 diabetes. If you need to have any type of x-ray or CT scan using a dye that is injected into your veins, you will need to temporarily stop taking Xigduo XR. Xigduo XR may cause a serious condition called lactic acidosis. Get emergency medical help if you have even mild symptoms such as: muscle pain or weakness, numb or cold feeling in your arms and legs, trouble breathing, stomach pain, nausea with vomiting, slow or uneven heart rate, dizziness, or feeling very weak or tired. You should not use Xigduo XR if you are allergic to dapagliflozin (Farxiga) or metformin (Glucophage, Actoplus Met, Avandamet, Glucovance, Jentadueto, Kombiglyze, Metaglip, and others), or if you have: moderate to severe kidney disease (or if you are on dialysis); or metabolic acidosis or diabetic ketoacidosis (call your doctor for treatment). If you need to have any type of x-ray or CT scan using a dye that is injected into your Continue reading >>

A Treatment For Adults With Type 2 Diabetes Mellitus, In Addition To Diet And Exercise. Xigduo Xr Is Not Recommended For Patients With Type 1 Diabetes Mellitus Or Diabetic Ketoacidosis.

A Treatment For Adults With Type 2 Diabetes Mellitus, In Addition To Diet And Exercise. Xigduo Xr Is Not Recommended For Patients With Type 1 Diabetes Mellitus Or Diabetic Ketoacidosis.

Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio, and metformin plasma levels generally >5 mcg/mL. Risk factors include renal impairment, concomitant use of certain drugs, age >65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information. If lactic acidosis is suspected, discontinue XIGDUO XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. Contraindications Warnings and Precautions Hypotension: Dapagliflozin causes intravascular volume contraction, and symptomatic hypotension can occur. Assess and correct volume status before initiating XIGDUO XR in patients with impaired renal function, elderly patients, or patients on loop diuretics. Monitor for hypotension. Ketoacidosis has been reported in patients with type 1 and type 2 diabetes receiving dapagliflozin. Some cases were fatal. Assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis, regardless of blood glucose level. If suspected, discontinue XIGDUO XR, evaluate and treat promptly. Before initiating XIGDUO XR, consider risk factors for ketoacidosis. Patients on XIGDUO XR may require monitoring and temporary discontinuation in situations known to predispose to ketoacidosis. Acute Kidney Injury and Impai Continue reading >>

Xigduo Xr 5/1000 | Healthdirect

Xigduo Xr 5/1000 | Healthdirect

Xigduo XR 5/1000 is a medicine containing the active ingredient(s) dapagliflozin + metformin. On this page you will find out more about Xigduo XR 5/1000, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS) You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance. Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions . Active ingredient in this medicine: dapagliflozin + metformin Xigduo XR 5/1000 modified release tablet, 56 This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data. Continue reading >>

More in diabetes